COVID rebound after Pfizer treatment likely due to robust immune response, study findsReuters • 10/06/22
Pfizer's Covid Sales Are Expected To Decline, Again — Is PFE Stock Now A Sell?Investors Business Daily • 10/03/22
Pfizer and BioNTech seek authorization of omicron-targeted booster for children aged 5 to 11Market Watch • 09/26/22
Pfizer and BioNTech seek FDA EUA for omicron-targeting booster for use in children aged 5 to 11Market Watch • 09/26/22
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of AgeBusiness Wire • 09/26/22